An EUA for Tocilizumab (Actemra) for COVID-19

Date: July 26, 2021
Issue #: 
1629Summary: 
The interleukin-6 (IL-6) receptor antagonist
tocilizumab (Actemra– Genentech) has received an
Emergency Use Authorization (EUA) from the FDA for
IV treatment of COVID-19 in hospitalized patients ≥2
years old who are receiving a systemic corticosteroid
and require supplemental oxygen, mechanical
ventilation, or extracorporeal membrane oxygenation
(ECMO). Tocil izumab has been approved by the FDA
for various indications, including rheumatoid arthritis
and juvenile idiopathic arthritis.

Source: The Medical Letter - July 9, 2021 Category: Drugs & Pharmacology Authors: admin Tags: Actemra baricitinib corticosteroids COVID-19 Dexamethasone Olumiant remdesivir Tocilizumab Source Type: research